Treatment of Advanced/Metastatic SRI-Positive Thymic Carcinoid — Typical or Slowly Progressing
This protocol addresses patients with advanced or metastatic carcinoid tumor of the thymus (typical carcinoid, or cases with slow radiological progression) that is positive on somatostatin receptor imaging, without atypical or significantly progressive features.
Clinical scenario
- Advanced or metastatic thymic carcinoid
- Typical carcinoid histology, or slowly radiologically progressing disease
- Somatostatin receptor imaging (SRI)-positive
- No atypical or significantly progressive features
First-line approach — partial overview
Management in this setting may include a watchful observation strategy in appropriate cases, or the use of somatostatin analogues as first-line medical therapy. Locoregional interventions are also part of the treatment landscape for selected patients.
The complete algorithm — including which option applies, sequencing, and full criteria — is available in the structured protocol.
References
DOI: 10.1016/j.annonc.2021.01.003
- SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
- Watchful follow-up may be considered in asymptomatic patients with slowly radiologically progressing LCs [V, C]
- Octreotide [long-acting release (LAR) 30 mg] and lanreotide (120 mg) are the two SSAs most commonly used in clinical practice.
- Multiple locoregional therapies including surgery, combined or not with SSAs, are recommended to decrease the tumour burden, to control hormonal secretions and to prevent local complications, as a first-line therapeutic approach in patients with advanced slowly progressing LC [V, B].
View source ↗